Biological Hematology

Altuviiio

Payments companies reported to CMS as associated with Altuviiio. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$3.1Massociated payments (2023-2025)

868clinicians with associated payments

5companies reporting

By year

2023 $740K

2024 $1.2M

2025 $1.2M

Payments reported as associated with Altuviiio, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Pediatric Hematology-Oncology $1.8M

Hematology & Oncology $591K

Hematology (Internal Medicine) $199K

Pediatrics $171K

Pediatrics (Nurse Practitioner) $114K

Family $98K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Altuviiio

These are the largest totals companies reported as associated with Altuviiio. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Guy Young	Bozeman, MT	Pediatric Hematology-Oncology	$240,618.62
Shveta Gupta	Orlando, FL	Pediatric Hematology-Oncology	$205,356.20
Maissaa Janbain	New Orleans, LA	Hematology & Oncology	$198,458.83
Doris Quon	Los Angeles, CA	Hematology (Internal Medicine)	$197,551.32
Vinod Balasa	Madera, CA	Pediatric Hematology-Oncology	$144,821.92
Vivek Sharma	Louisville, KY	Hematology & Oncology	$130,493.96
Akshat Jain	Redlands, CA	Pediatric Hematology-Oncology	$128,070.00
Vanessa Salinas-Luna	Orange, CA	Pediatric Hematology-Oncology	$122,960.45
Guillermo Deangulo	Miami, FL	Pediatric Hematology-Oncology	$101,314.44
Joanna Davis	Miami, FL	Pediatric Hematology-Oncology	$92,230.09

Prescribed Altuviiio?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.